{"id":{"repo_id":"nus","oai_identifier":"oai:scholarbank.nus.edu.sg:10635/310436"},"canonical_url":"https://search.dev.ndltd.org/etd/nus/oai:scholarbank.nus.edu.sg:10635/310436","repository":{"repo_id":"nus","name":"National University of Singapore","base_url":"https://scholarbank.nus.edu.sg/oai/request"},"display":{"title":"SAFETY, EFFICACY, AND IMMUNOGENICITY OF SARS-COV-2 MRNA VACCINES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS","abstract":"mRNA vaccines mark a significant advancement in immunization, extending potential applications beyond COVID-19. Although mRNA vaccines are effective in healthy individuals, their safety and efficacy in autoimmune conditions like systemic lupus erythematosus (SLE), a type 1-interferon-driven disease, remain uncertain, as their mechanism of inducing T-cell-mediated responses and antibody production may risk exacerbating underlying immune dysregulation. This study evaluated immune responses to mRNA COVID-19 vaccines in SLE patients and healthy controls through clinical assessments, serological testing, antibody quantification, and flow cytometric analysis of immune cell subsets. The vaccines were well-tolerated in SLE patients, with no disease flares reported. While antibody responses were reduced, particularly among those receiving mycophenolate mofetil, notable B and T cell alterations reflected preserved adaptive immunity. These findings support the safety of mRNA vaccines in SLE and highlight the importance of tailored monitoring in immunosuppressed populations.","abstract_html":"mRNA vaccines mark a significant advancement in immunization, extending potential applications beyond COVID-19. Although mRNA vaccines are effective in healthy individuals, their safety and efficacy in autoimmune conditions like systemic lupus erythematosus (SLE), a type 1-interferon-driven disease, remain uncertain, as their mechanism of inducing T-cell-mediated responses and antibody production may risk exacerbating underlying immune dysregulation. This study evaluated immune responses to mRNA COVID-19 vaccines in SLE patients and healthy controls through clinical assessments, serological testing, antibody quantification, and flow cytometric analysis of immune cell subsets. The vaccines were well-tolerated in SLE patients, with no disease flares reported. While antibody responses were reduced, particularly among those receiving mycophenolate mofetil, notable B and T cell alterations reflected preserved adaptive immunity. These findings support the safety of mRNA vaccines in SLE and highlight the importance of tailored monitoring in immunosuppressed populations.","abstract_has_math":false,"creators":["PREETI DHANASEKARAN"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2024,"date_issued":"2024-12-04","date_published":"2024-12-04","updated_at":"2026-07-24T03:32:04Z","subjects":["COVID-19","SLE","mRNA vaccines"],"languages":[],"rights":[],"rights_urls":["https://scholarbank.nus.edu.sg/bitstreams/82ae9909-450f-4daa-b429-c5a3b90ad456/download"],"identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:creator","label":"Author","values":["PREETI DHANASEKARAN"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.issued","label":"Date","values":["2024-12-04"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["https://scholarbank.nus.edu.sg/handle/10635/310436"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["COVID-19","SLE","mRNA vaccines"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:rights","label":"Dc Rights","values":["https://scholarbank.nus.edu.sg/bitstreams/82ae9909-450f-4daa-b429-c5a3b90ad456/download"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://scholarbank.nus.edu.sg/bitstreams/25ff820a-6d9a-49e3-9f5d-b543e4c4f15a/download"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["mRNA vaccines mark a significant advancement in immunization, extending potential applications beyond COVID-19. Although mRNA vaccines are effective in healthy individuals, their safety and efficacy in autoimmune conditions like systemic lupus erythematosus (SLE), a type 1-interferon-driven disease, remain uncertain, as their mechanism of inducing T-cell-mediated responses and antibody production may risk exacerbating underlying immune dysregulation. This study evaluated immune responses to mRNA COVID-19 vaccines in SLE patients and healthy controls through clinical assessments, serological testing, antibody quantification, and flow cytometric analysis of immune cell subsets. The vaccines were well-tolerated in SLE patients, with no disease flares reported. While antibody responses were reduced, particularly among those receiving mycophenolate mofetil, notable B and T cell alterations reflected preserved adaptive immunity. These findings support the safety of mRNA vaccines in SLE and highlight the importance of tailored monitoring in immunosuppressed populations."]},{"key":"dc:format.checksum.md5","label":"Dc Format Checksum Md5","values":["9f3c6f2aa8f96291ef77b0a18484521d","22b8380183eb8b373203dd89daa56829","61ea45dbe19c0fd2046a8ea5f6490123"]},{"key":"dc:title","label":"Title","values":["SAFETY, EFFICACY, AND IMMUNOGENICITY OF SARS-COV-2 MRNA VACCINES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS"]}]}],"canonical_facts":{"dc:creator":["PREETI DHANASEKARAN"],"dc:date.issued":["2024-12-04"],"dc:description.abstract":["mRNA vaccines mark a significant advancement in immunization, extending potential applications beyond COVID-19. Although mRNA vaccines are effective in healthy individuals, their safety and efficacy in autoimmune conditions like systemic lupus erythematosus (SLE), a type 1-interferon-driven disease, remain uncertain, as their mechanism of inducing T-cell-mediated responses and antibody production may risk exacerbating underlying immune dysregulation. This study evaluated immune responses to mRNA COVID-19 vaccines in SLE patients and healthy controls through clinical assessments, serological testing, antibody quantification, and flow cytometric analysis of immune cell subsets. The vaccines were well-tolerated in SLE patients, with no disease flares reported. While antibody responses were reduced, particularly among those receiving mycophenolate mofetil, notable B and T cell alterations reflected preserved adaptive immunity. These findings support the safety of mRNA vaccines in SLE and highlight the importance of tailored monitoring in immunosuppressed populations."],"dc:format.checksum.md5":["9f3c6f2aa8f96291ef77b0a18484521d","22b8380183eb8b373203dd89daa56829","61ea45dbe19c0fd2046a8ea5f6490123"],"dc:identifier.uri":["https://scholarbank.nus.edu.sg/bitstreams/25ff820a-6d9a-49e3-9f5d-b543e4c4f15a/download"],"dc:relation.isreferencedby":["https://scholarbank.nus.edu.sg/handle/10635/310436"],"dc:rights":["https://scholarbank.nus.edu.sg/bitstreams/82ae9909-450f-4daa-b429-c5a3b90ad456/download"],"dc:subject":["COVID-19","SLE","mRNA vaccines"],"dc:title":["SAFETY, EFFICACY, AND IMMUNOGENICITY OF SARS-COV-2 MRNA VACCINES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS"],"dc:type":["Thesis"]},"updated_at":"2026-07-24T03:32:04Z"}